In active ulcerative colitis, risankizumab induced and maintained remission.

IF 19.6 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

Annals of Internal Medicine Pub Date : 2024-11-01 Epub Date: 2024-11-05 DOI:10.7326/ANNALS-24-02768-JC

Alessandro Pedicelli, Waqqas Afif

引用次数: 0

Abstract

Source citation: Louis E, Schreiber S, Panaccione R, et al; INSPIRE and COMMAND Study Group. Risankizumab for ulcerative colitis: two randomized clinical trials. JAMA. 2024;332:881-897. 39037800.

查看原文本刊更多论文

在活动性溃疡性结肠炎中，利桑珠单抗可诱导并维持病情缓解。

来源引用：Louis E, Schreiber S, Panaccione R, et al; INSPIRE 和 COMMAND 研究小组。利桑珠单抗治疗溃疡性结肠炎：两项随机临床试验。美国医学会杂志》。2024;332:881-897.39037800.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Internal Medicine 医学-医学：内科

CiteScore

23.90

自引率

1.80%

发文量

1136

审稿时长

3-8 weeks

期刊介绍： Established in 1927 by the American College of Physicians (ACP), Annals of Internal Medicine is the premier internal medicine journal. Annals of Internal Medicine’s mission is to promote excellence in medicine, enable physicians and other health care professionals to be well informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. To achieve this mission, the journal publishes a wide variety of original research, review articles, practice guidelines, and commentary relevant to clinical practice, health care delivery, public health, health care policy, medical education, ethics, and research methodology. In addition, the journal publishes personal narratives that convey the feeling and the art of medicine.